Trafficking of parasitic nematode ion channels
寄生线虫离子通道的贩运
基本信息
- 批准号:9165333
- 负责人:
- 金额:$ 22.5万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2016
- 资助国家:美国
- 起止时间:2016-06-03 至 2018-05-31
- 项目状态:已结题
- 来源:
- 关键词:AffectAgonistAmino Acid SequenceAnthelminticsAppearanceBeliefCaenorhabditis elegansCell LineCell NucleusCell membraneCell surfaceCellsCellular biologyChloride ChannelsDevelopmentDominant-Negative MutationDrug ReceptorsDrug TargetingDrug resistanceEndocytosisEndosomesExcisionExposure toHaemonchusHumanInfectionIon ChannelIvermectinLeadLengthLevamisoleLigandsLocationLysosomesMediatingMembraneModelingMutateNematodaNervous system structureNicotineNicotinic ReceptorsParasite resistanceParasitesParasitic nematodePathway interactionsPatternPharmaceutical PreparationsPharmacotherapyPopulationPotassium ChannelProcessPropertyProteinsPyrantelRecyclingReportingResistanceRoleSignal TransductionTestingTransgenic OrganismsUp-RegulationVaccinesVeterinary MedicineWorkhealth economicsin vitro testingin vivoinsightlate endosomenovelreceptorreceptor functiontraffickinguptake
项目摘要
Parasitic nematodes infect a large proportion of the world's population and contribute to
the continuing poor health and economic under-development of the affected
populations. Control and the planned elimination of these infections is dependent on
effective anthelmintic drugs as no vaccines are available. At present, it is not properly
understood how the drugs work and resistance to them is an increasing threat. It is
known that many of the drugs act at receptors and ion channels in the parasites
nervous system. The aim of this proposal is to test the hypothesis that the normal
processes by which these receptors and ion channels are directed to their correct
locations within the cell may be subverted in resistant parasites and may be affected by
the drugs themselves. Two drugs will be the focus of the studies, levamisole and
emodepside. Levamisole acts at a subset of nicotinic acetylcholine receptors and
emodepside at SLO-1 potassium channels. Truncated forms of subunits of the
levamisole receptor have been identified and their ability to affect the location and
function of the receptors will be tested in vitro and in vivo. Specific amino-acid sequence
motifs that cause endocytosis from the plasma membrane are present in some
truncated levamisole receptor subunits, but not the full-length versions – the contribution
of these motifs to altered trafficking will be examined. Similar motifs are present in SLO-
1 from some parasite species, but not others, which suggests that the function of the
channel may be subtly different between species. This may be reflected in slightly
different effects of emodepside. This will be tested by careful examination of the sub-
cellular expression pattern of the different SLO-1 channels, and by testing the effects of
mutating these motifs on that expression pattern. The project will reveal new aspects of
the cell biology of drug targets in parasitic nematodes and provide new insights into how
these may be perturbed in resistance.
寄生线虫感染了世界上很大一部分人口,并导致
受影响者的健康状况持续不佳,经济不发达,
人口。控制和有计划地消除这些感染取决于
有效的驱虫药物,因为没有疫苗可用。目前,
了解药物的工作原理,对它们的耐药性是一个日益严重的威胁。是
已知许多药物作用于寄生虫的受体和离子通道
神经系统这项建议的目的是检验假设,即正常
这些受体和离子通道被引导到它们的正确的
细胞内的位置可能在抗性寄生虫中被破坏,
毒品本身。两种药物将是研究的重点,左旋咪唑和
表情符号。左旋咪唑作用于烟碱乙酰胆碱受体的亚类,
在SLO-1钾通道中。亚基的截短形式
左旋咪唑受体已被确定,它们的能力,影响的位置和
将在体外和体内测试受体的功能。特异性氨基酸序列
引起质膜内吞作用的基序存在于一些细胞中,
截短的左旋咪唑受体亚基,但不是全长版本-贡献
将审查这些动机与改变贩运的关系。类似的基序也存在于SLO中-
1从一些寄生虫物种,但不是其他人,这表明,功能的
不同物种之间的通道可能略有不同。这可能反映在轻微的
Emodepside的不同效果这将通过仔细检查子-
不同SLO-1通道的细胞表达模式,并通过测试
在表达模式上改变这些基序。该项目将揭示新的方面
药物靶向寄生线虫的细胞生物学,并提供了新的见解
这些电阻可能会受到干扰。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Adrian J Wolstenholme其他文献
Adrian J Wolstenholme的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Adrian J Wolstenholme', 18)}}的其他基金
Anthelmintics: From discovery of new drugs to modes of action and resistance
驱虫药:从新药的发现到作用方式和耐药性
- 批准号:
8646022 - 财政年份:2014
- 资助金额:
$ 22.5万 - 项目类别:
The antifilarial activity of ivermectin and diethylcarbamizine
伊维菌素和二乙基卡巴嗪的抗丝虫活性
- 批准号:
8756401 - 财政年份:2014
- 资助金额:
$ 22.5万 - 项目类别:
The antifilarial activity of ivermectin and diethylcarbamizine
伊维菌素和二乙基卡巴嗪的抗丝虫活性
- 批准号:
8901920 - 财政年份:2014
- 资助金额:
$ 22.5万 - 项目类别:
Can drug targets from parasitic nematodes be usefully expressed in C. elegans?
寄生线虫的药物靶标能否在秀丽隐杆线虫中有效表达?
- 批准号:
8422969 - 财政年份:2012
- 资助金额:
$ 22.5万 - 项目类别:
Can drug targets from parasitic nematodes be usefully expressed in C. elegans?
寄生线虫的药物靶标能否在秀丽隐杆线虫中有效表达?
- 批准号:
8302014 - 财政年份:2012
- 资助金额:
$ 22.5万 - 项目类别:
相似国自然基金
Agonist-GPR119-Gs复合物的结构生物学研究
- 批准号:32000851
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
- 批准号:
24K12256 - 财政年份:2024
- 资助金额:
$ 22.5万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
- 批准号:
24K19176 - 财政年份:2024
- 资助金额:
$ 22.5万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
- 批准号:
10578068 - 财政年份:2023
- 资助金额:
$ 22.5万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 22.5万 - 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
- 批准号:
10650593 - 财政年份:2023
- 资助金额:
$ 22.5万 - 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
- 批准号:
10649275 - 财政年份:2023
- 资助金额:
$ 22.5万 - 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
- 批准号:
10734158 - 财政年份:2023
- 资助金额:
$ 22.5万 - 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
- 批准号:
10784209 - 财政年份:2023
- 资助金额:
$ 22.5万 - 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
- 批准号:
10580259 - 财政年份:2023
- 资助金额:
$ 22.5万 - 项目类别:
Fentanyl Addiction: Individual Differences, Neural Circuitry, and Treatment with a GLP-1 Receptor Agonist
芬太尼成瘾:个体差异、神经回路和 GLP-1 受体激动剂治疗
- 批准号:
10534864 - 财政年份:2023
- 资助金额:
$ 22.5万 - 项目类别: